Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer
The purpose of this study is to evaluate the objective response rate and safety in platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patients treated with vinorelbine and gemcitabine combination chemotherapy.
Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer
DRUG: Vinorelbine and Gemcitabine
Objective response rate (complete response and partial response), radiologically assessed response every two cycles, according to RECIST ver 1.1 criteria and serologically assessed CA 125 response every two cycles, according to Rustin's criteria, 16 weeks
Progression Free Survival, fom the date of enrollment until the date of confimed progressive disease or death, 6months|overall survival, from the date of enrollment to death any cause, 1year|Frequency and severity of adverse effects, assesed by the NCI-CTCAE ver 3.0, every cycle , from enrollment until death
Other objectives of this study are to evaluate Progression-free survival and measure CA-125 response rate.